Patient Activity Scale II (PAS II) for Rheumatoid Arthritis
Patient-reported outcome measure for RA disease activity. Combines HAQ-II (disability) and patient global VAS. Score 0–10. Validated and recommended by ACR for routine RA monitoring. Correlates with DAS28 and CDAI.
Score interpretation
PAS-II ≤ 0.25 — remission
→ Continue current DMARD therapy; monitor at 3–6 monthly intervals; consider very cautious tapering after sustained remission ≥6 months in consultation with rheumatologist
PAS-II 0.26–3.70 — low disease activity
→ Maintain therapy; review at 3-monthly intervals; assess treatment targets; patient education on joint protection and exercise
PAS-II 3.71–7.99 — moderate disease activity
→ Review and adjust DMARD therapy; treat-to-target strategy; consider addition of biologic or JAK inhibitor if inadequate response to csDMARDs; physiotherapy and occupational therapy referral
PAS-II ≥ 8.0 — high disease activity
→ Urgent rheumatology review; optimise therapy (biologics: anti-TNF, rituximab, abatacept, IL-6 inhibitor, JAK inhibitors); corticosteroid bridge; check adherence; screen for infection before escalation; multidisciplinary team management
Interpretation bands for the PAS II. Apply clinical judgement and local guidance.
References
- Wolfe F, Michaud K. The Patient Activity Scale and the Patient Activity Scale-II: better self-assessment questionnaires for disease activity in patients with rheumatoid arthritis. Arthritis Care Res. 2010;62(7):1019–1026.
Related
Curated clinical cross-links plus same-class fallbacks.
- Hydroxychloroquine · Aminoquinoline — Malaria Prophylaxis / SLE / Rheumatoid Arthritis
- Pindolol · Non-selective β-blocker (with intrinsic sympathomimetic activity)
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Acetazolamide (Ménière's Disease) · Carbonic Anhydrase Inhibitor (Diuretic)
- Zinc acetate · Zinc salt (Wilson's disease)
- Sulfasalazine · Aminosalicylate / Disease-Modifying Antirheumatic Drug (DMARD)
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.